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INTRODUCTION 
To pursue optimal drug action, functional molecules 
could be transported by a carrier to the site of action and 
released to perform their task. Non-ionic surfactant 
vesicles known as niosomes are microscopic lamellar 
structures formed on admixture of a non-ionic surfactant, 
cholesterol and dicetyl phosphate with subsequent 
hydration in aqueous media.  Proniosomes offer a 
versatile vesicle drug delivery concept with potential for 
delivery of drugs via different routes specially 
Transdermal route. An attempt has been made to 
formulate Proniosomes of Levofloxacin for ocular drug 
delivery system. Proniosomes minimizes problems of 
niosomes physical stability such as aggregation, fusion 
and leaking and provide additional convenience in 
transportation, storage and dosing.1-5 
MATERIAL AND METHODS 
Material: Levofloxacin was obtained gift sample from 
Ranbaxy Laboratory Dewas, M.P India, lecithin was 
purchsed from Sigma aldrise, USA Spans were obtained 
from Zydus Cadila, Ahmadabad and Cholesterol was 
purchased from Rankem Laboratory, Mumbai. Other 
solvents were purchased from analytical grade in local 
firms. 
Methods 
PREFORMULATION STUDIES OF DRUG
6-9
 
Identification Test: The different identification tests as 
per I.P. are done. 
Physical appearance: The drug levofloxacin powder 
was examined for its organoleptic properties like color 
and odor.  
Solubility study: The sample was qualitatively tested for 
its solubility in various solvents. It was determined by 
taking 2 mg of drug sample in 5 ml of solvent as water, 
methanol, ethanol, phosphate buffer, HCl, etc., in small 
test tubes and well solubilized by shaking.  
Melting point determination: 
Melting point of levofloxacin was determined by 
capillary method. A small quantity of powder was placed 
into a fusion tube. The tube was placed in the melting 
point determining apparatus (Tempo, Mumbai). The 
temperature of the apparatus was gradually increased 
automatically and the temperature at which powder 
started to melt and the temperature when all the powder 
gets melted were recorded57.  
Development of Calibration Curve for levofloxacin: 
a) A stock solution of 1mg/ml of levofoxacin was 
prepared by dissolving 100 mg of drug in 100 ml of 
STF (pH 7.4) and sonicated for few seconds.  
b) The stock solution was serially diluted to get 
solutions in the range of 2-10 µg/ml and λ max of 
the solution was found out. 
c) The λ max of the solution was found out. 
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d) The absorbencies of the different diluted solutions 
were measured in a UV spectrophotometer. 
Determination of partition coefficient  
The partition behavior of drug was examined in n-
Octanol: PBS (pH 7.4). It was determined by taking 5 
mg of drug in separating funnel containing 10 ml 
portions of each n-Octanol and 10 ml of PBS (pH 7.4). 
The separating funnels were shaken for 2 hrs in a wrist 
action shaker for equilibration. Two phases were 
separated and the amount of the drug in aqueous phase 
was analyzed spectrophotometrically at 293 nm after 
appropriate dilution. The partition coefficient of the drug 
in phases was calculated by using formula:   
 
Compatibility Studies 
A Compatibility study was carried out in order to 
establish, that there would be no   interaction between the 
drug and excipients used in the formulation. These 
studies were carried out by    FT IR studies. The drug, 
individual polymer and 1:1 physical mixtures of drug 
and polymer (each 10 mg) were   prepared and mixed 
with 400 mg of potassium bromide. About 100 mg of 
this mixture was compressed to form a transparent pellet 
using a hydraulic press at 10 tones pressure. It was 
scanned from 4000 to 400 cm-1 in a FTIR 
spectrophotometer. The IR spectra of physical mixtures 
were compared with those of pure drug and polymers to 
detect any appearance or disappearance of peaks. 
Similarly, IR spectrums of the physical mixture were 
scanned after 2 months and were matched with the 
original ones. 
FORMULATION OF PRONIOSOMES
10-14
 
Proniosomal gel was prepared by a coacervation-phase 
separation method. Precisely weighed amounts of 
surfactant, lecithin, cholesterol, poly ethylene oxalate 
and drug were taken in a clean and dry wide mouthed 
glass vial of 5.0 ml capacity and alcohol (2.5 ml absolute 
ethanol) was added to it. After warming, all the 
ingredients were mixed well with a glass rod; the open 
end of the glass bottle was covered with a lid to prevent 
the loss of solvent from it and warmed over water bath at 
60-70°C for about 5 min until the surfactant mixture was 
dissolved completely. Then the aqueous phase (0.1% 
glycerol solution) 1.6ml was added and warmed on a 
water bath till a clear solution was formed which was 
converted into proniosomal gel on cooling. The gel so 
obtained was preserved in the same glass bottle in dark 
conditions for characterization. 
Compositions of proniosomal gel formulations are given 
in Table 1. 
 
Table 1:  Composition of proniosomal formulations prepared 
Proniosomal 
Code 
Drug 
(mg) 
Cholesterol 
(mg) 
Lecithin 
(mg) 
Span PEO 
mg 40 60 
PN1 10 20 50 10 -- 10 
PN2 10 20 20 20 -- 10 
PN3 10 20 20 30 -- 10 
PN4 10 20 20 -- 10 10 
PN5 10 20 20 -- 20 10 
PN6 10 20 20 -- 30 10 
 
EVALUATION OF PRONIOSOMES OF 
LEVOFLOXACIN 
Optical microscopy and vesicle size determination
10
 
A drop of niosomal dispersion prepared from 
proniosomes was spread on a glass slide and examined 
for the vesicle structure and presence of insoluble drug 
crystals under the light microscope with varied 
magnification power. Photomicrographs were taken for 
niosomes using a digital camera with 5X optical 200 m. 
The proniosomal gel (10 mg) was hydrated with PBS (10 
ml) in a small test tube by manual shaking for 5 min and 
the resulting niosomes were observed under optical 
microscope at 100 X magnification. The average size of 
vesicles was measured using calibrated ocular and stage 
micrometer in the microscope. 
Determination of Encapsulation Efficiency
11-12
 
Percent encapsulation efficiency (EE) was determined by 
centrifugal method56.  The proniosomal gel was 
converted to a niosomal dispersion, which was 
centrifuged (18000 rpm) for 40 min at 5oC in order to 
separate unentrapped drug.  The supernatant was taken 
and diluted with PBS (pH7.4). The drug concentration in 
the resulting solution was assayed 
spectrophotometrically at 293 nm. The percentage of 
drug encapsulation was calculated by the following:  
EE (%) = [(Ct - Cf)/ Ct] × 100, 
Where Ct is the concentration of total drug and Cf is the 
concentration of unentrapped drug. 
Scanning electron microscopy
12-13
 
The niosomes formed from the hydration of proniosomal 
gel were mounted on an aluminum stub with double-
sided adhesive carbon tape.  The vesicles were then 
sputter-coated with gold/palladium using a vacuum 
evaporator and examined with the scanning electron 
microscope equipped with a digital camera at 25kV 
accelerating voltage. 
In vitro release studies using dialysis cellophane 
membrane
12-14
 
In vitro release studies on proniosomal gel were 
performed using Franz-diffusion cell. The capacity of 
receptor compartment was 15 ml. The area of donor 
layer aqueous in drug of Amount
layerorganic  in drug of Amount
K  t,Coefficien Partition 
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compartment exposed to receptor compartment was 
1.41cm2. The dialysis cellophane membrane was 
mounted between the donor and receptor compartment. 
A weighed amount of proniosomal gel was placed on one 
side of the dialysis membrane. The receptor medium was 
STF (stimulated tear fluid) pH 7.4. The receptor 
compartment was surrounded by a water jacket to 
maintain the temperature at 37±1oC. Heat was provided 
using a thermostatic hot plate with a magnetic stirrer. 
The receptor fluid was stirred by a Teflon-coated 
magnetic bead fitted to a magnetic stirrer. At each 
sampling interval, samples were withdrawn and were 
replaced by equal volumes of fresh receptor fluid on each 
occasion. Samples withdrawn were analyzed 
spectrophotometrically at 293 nm. 
 
Ocular Irritancy Test 
15
 
The  optimized  formulation  was  evaluated  for  in  vivo 
performance  in  animal  model  (Albino  rabbits). Three 
rabbits were used for this study. They  were  housed  and 
maintained  in  the  animal  house  at room  temperature  
(27ºC)  during  the  period  of  the  study. They were fed 
with standard diet and water.  The animals were placed 
in cages and the eyes were marked as test and control. 
The control group received no  sample  and  the  test eye  
received  the  formulation ,  and  the  eyes  were 
observed  for  the ocular  irritancy  (includes  the 
macroscopic observation of cornea, iris, and 
conjunctiva). 
 
RESULT AND DISCUSSION 
Identification 
Physical Appearance: The drug (Levofloxacin) powder 
was examined for its organoleptic properties like colour 
and odour and it was observed that Levofloxacin was 
yellowish crytalline powder. 
Solubility study: The sample was qualitatively tested for 
its solubility in various solvents. It was determined by 
taking 2 mg of drug sample in 5 ml of solvent as water, 
methanol, ethanol, ethyl acetate etc., in small test tube 
and well solubilized by shaking. Solubility study in 
different solvents at room temperature revealed that it is 
soluble in, ethanol, methanol, 0.1N NaOH, Glacial acetic 
acid etc and it is insoluble in distilled water (table. 2).
 
Table 2: Solubility studies of levofloxacin with different solvent 
Sr. No. Compound Ratio Solubility 
1 Levofloxacin: Water 1:10 Slightly Soluble 
2 Levofloxacin: Methanol 1:10 Completely soluble 
3 Levofloxacin: Ethanol 1:10 Sparingly soluble 
4 Levofloxacin: Dichloromethane 1:10 Slightly soluble 
5 Levofloxacin: Glacial acetic acid 1:10 Completely soluble 
6 Levofloxacin: 0.1N NaOH 1:10 Completely soluble 
7 Lexvofloxacin : Ethyl acetate 1:10 Slightly soluble 
 
Preparation of calibration curves 
Levofloxacin solution was scanned in the U.V. range of 
200-400 nm using Sistronic UV Visible 
spectrophotometer. The spectrophotometric method of 
analysis of Levofloxacin at max 293 nm was found to be 
reproducible and highly sensitive. The standard curves of 
Levofloxacin was prepared in STF (pH 7.4), at max 293 
nm. The data were regressed to obtain the straight line. 
The correlation coefficient greater than 0.99 was 
observed, which indicated that, the drug follows Beer-
Lambert's law in the concentration range of 2-20 g/ml. 
Preparation of Calibration Curve of Levofloxacin in 
STF (PBS pH 7.4) 
The calibration curve was plotted between the 
concentration and absorbance. The calibration curve of 
2-20µg/ml was carried out. The slope and intercept of the 
calibration curve were 0.051 and 0.008 respectively. The 
correlation coefficient ‘r2’ values were calculated as 
0.999 as shown in table 3 and figure 1.
 
Table 3: Standard Curve of Levofloxacin in Phosphate Buffer Solution (pH 7.4) at 293 nm 
S.No. Drug Conc.      (µg/ml) Absorbance Statistical Parameters 
1. 2 
0.102 
 
Correlation coefficient- 
r = 0.999 
Slope m = 0.051 
Intercept c = 0.008 
Equation of Line- 
y = 0.051 X + 0.008 
2. 4 0.210 
3. 6 0.321 
4. 8 0.421 
5. 10 0.522 
6. 12 0.629 
7. 14 
    0.721 
 
8. 16 0.832 
9. 18 0.932 
10. 20 1.02 
Dhangar et al                                     Journal of Drug Delivery & Therapeutics; 2014, 4(5), 182-189 185 
© 2011-14, JDDT. All Rights Reserved                                                  ISSN: 2250-1177                                              CODEN (USA): JDDTAO 
 
Fig 1: Calibration curve of   Levofloxacin   in 
phosphate buffer at max 293 
Melting point determination:  Melting point of 
Levofloxacin was found at 218 ºC 
Partition coefficient: Partition coefficient studies are 
carried out to find out extent of drug transfer in the 
aqueous and the other non aqueous layer. This 
phenomenon usually is done to obtain the drug 
concentration in the either layer. Partition coefficient 
value of Levofloxacin also revealed its hydrophobic 
nature which is listed a as shown in table 4.   
Table 4: Partition coefficient values of Levofloxacin 
S. 
No. 
Solvent system 
Partition 
Coefficient 
1. n-Octanol/Distilled water 0.666 
2. n-Octanol/PBS (pH 7.4) 0.459 
 
Fourier-Transform Infra Red spectroscopy (FTIR)  
The IR spectrum of drug substance was authenticated 
using IR spectroscopy. The   presence of characteristic 
peaks associated with specific structural characteristics 
of the drug molecule was noted. Various peaks of the 
drug are shown in figure 2 and shown in table 5 with its 
band frequencies. 
 
 
 
Fig 2:   FT-IR of Levofloxacin 
 
Table 5:  Important band frequencies in IR spectrum of Levofloxacin 
S. No. Named Group 
Reported Band 
frequency (cm
-1
) 
Band frequency obtained (cm
-
1
) 
1. C-O(cyclic ether) 1200 1055 
2. COOH group 1680 1620 
3 C=O 1700 1725 
4. C-N 1200 1293 
5. N-H(piprazine) 3200 3398 
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Fig 3: FT-IR of drug (Levofloxacin) and surfactant (span 60) 
 
FT-IR Spectra of Levofloxacin,Span physical mixture of 
drug : carrier and F4 formulation were recorded. The 
Levofloxacin present in the formulation F4 was 
confirmed by FT-IR spectra.The characteristic peaks due 
to pure Levofloxacin shows IR absorption at 1055cm-
1(C-O stretching),1620cm-1COOH carboxylic 
group,1725cm-1(C=O stretching), 1293cm-1(C-N 
stretching),3398cm-1{N-H(piprazine)bending}. All these 
peaks have appeared in pure levofloxacin, physical 
mixture and formulation indicating no chemical 
interaction between levofloxacin and carrier. It also 
confirmed that the stability of drug during formulation. 
EVALUATION OF PREPARED PRONIOSOMES 
OF LEVOFLOXACIN 
Optical Microscopy and Vesicle Size Determination 
The photomicrographs of  hydrated PN1 and PN3  
proniosomal formulations, composed of Span 40 and 
cholesterol in  1:1 and 2:1  ratios, are shown in  Figure 4 
and  Figure 5 respectively.  The photographs reveal that 
the niosomes are unilamellar vesicles having spherical 
shape and no aggregation or agglomeration is observed. 
Apparently, PN1 niosomal formulation gives vesicles of 
larger sizes. 
 
Fig  4.  Photomicrograph of hydrated PN1 
(proniosomal formulation) 
 
Fig 5.  Photomicrograph of hydrated PN2 
(proniosomal formulation) 
 
% Encapsulation Efficiency of levofloxacin 
proniosomes  
Proniosomes prepared with non-ionic surfactants of alkyl 
ester Span (sorbitan esters) 40 and 60 were utilized to 
determine the encapsulation of associated levofloxacin. 
As shown in Table-8, encapsulation efﬁciency of 
proniosomes formed from span 40 exhibits a very high 
value and the entrapment efficiency was found to be 
highest with the formulation PN3. These Span 
surfactants give the least leaky proniosomes as have the 
highest phase transition temperature. This result was 
consistent with the entrapment efﬁciency of levofloxacin 
in proniosomes incorporated with Span 40. Most of the 
surfactants used to make non-ionic surfactant vesicles 
have a low aqueous solubility. However, freely soluble 
non-ionic surfactants such as Span can form the micelles 
on hydration in the presence of cholesterol .The 
encapsulation of levofloxacin can be entrapped into 
proniosomes composed of span60 however, the 
encapsulation efﬁciency was relatively low as compared 
to those composed of Span40 (Table -6). 
Soya lecithin was selected over egg lecithin because the 
former gives vesicles of larger size, possibly due to 
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differences in the intrinsic composition of soya and egg 
derived lecithin. Preparations with a white semi-solid 
appearance were obtained with span and cholesterol. 
Incorporation of lecithin results in a gel-like appearance.  
The types of alcohol affect the size of niosomal vesicles 
as well; ethanol gave the largest size vesicles. The larger 
size with ethanol is due to the slower phase separation 
because of its greater solubility in water. 
 
Table 6: physicochemical characterization of 
proniosome batches of Levofloxacin 
S.No. Proniosomal code  Encapsulation efficiency 
1. PF1 95.67 
2. PF2 96.71 
3. PF3 97.12 
4. PF4 78.62 
5. PF5 81.45 
6. PF6 85.51 
 
 
 
 
Fig 6: % of encapsulation efficiency of levofloxacin 
proniosomes 
Scanning electron Microscopy: 
Shape and surface characteristic of proniosome were 
examined by Scanning Electron Microscopy analysis. 
Scanning electron microscopy shows the porous surface 
of the pure levofloxacin particles (figure 7), this makes 
them effective carrier and provides more surface area for 
the coating of the surfactant mixture. Surface 
morphology illustrates the smooth surface of proniosome 
formulation. Preparing proniosomes on levofloxacin was 
formulate in different surfactant like span 20 and span 40 
also being include lecithin but it was necessary that the 
solution be incorporated in very small amounts and 
complete drying be ensured before further additions are 
made. 
 
 
 
Fig 7: SEM of Levofloxacin Proniosomes: 
 
 
 
 
Fig 8: In-vitro release of all formulation 
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In Vitro release studies of levofloxacin proniosomes 
The release study was conducted for all the six 
formulations as shown in the figure 8. All of the 
formulations were found to have a linear release and the 
formulations were found to provide approximately 90% 
release within a period of 24 hours. Cholesterol, which 
has a property to abolish the gel to liquid transition of 
niosomes,this found to prevent the leakage of drug from 
the proniosomal formulation.The slower release of drug 
from the multilamellar vesicles consist of several 
concentric sphere of bilayer separated by aqueous 
compartment .The above specified three best 
formulations PN3,PN5, and PN6  were found to give a 
cumulative release of  92.092%,92.437%,and92.438% 
respectively over a period of 24 hrs 
In-vivo Ocular Irritancy test 
Ocular Irritancy Test of Levofloxacin Proniosome  
The potential ocular irritancy test of proniosomal 
formulations PN1, PN2 and PN3 were evaluated by 
observing them for any redness, inflammation, or 
increased tear production, upon application to the eyes of 
albino rabbits. There is no irritancy effect on PN3. The 
miner redness was observed on PN1 and PN2. 
 
Fig 9. PN 1 Left Eye 
 
 
Fig 10: PN 10 Left Eye 
 
 
Fig 11:  PN 3 Left Eye 
  
CONCLUSION 
Proniosomes of Levofloxacin were prepared by 
coacervation-phase separation method. The drug 
encapsulation efficiency was studied for all the six 
formulations represented in table 8. The entrapment 
efficiency was found to be highest with the formulation 
PF3 (97.12%), which may have an optimum surfactant 
ratio to provide a high entrapment of levofloxacin. 
The release study was conducted for all the six 
formulations as shown in the Figure 9. Most of the 
formulations were found to have a linear release and the 
formulations were found to provide approximately 90% 
release within a period of 24 hours. The formulation 
which have optimum ratio PN3 was found to sustain the 
drug release than other formulations. Among all 
formulations PN3 was selected as best formulation 
because of its highest entrapment efficiency and 
consistent release profile of levofloxacin. 
Vesicles with smaller diameter are believed to better 
permeate through the skin as smaller vesicles tend to fuse 
readily. Shape and surface characteristic of proniosome 
were examined by Scanning Electronic Microscopy 
analysis. Surface morphology showed the smooth surface 
of optimised proniosomal formulation Figure.8. On 
conclusion,this novel drug delivery system ,Proniosome 
as compared to noisome suspension, represent a 
significant improvement by eliminating physical stability 
problems, such as aggregation or fusion of vesicle and 
leaking of entrapped drug during long term storage. 
Proniosome derived niosomes are superior in their 
convenience if storage, transport and dosing as compared 
to niosomes prepared by conventional methods.
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